Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy

Clinical and Experimental Rheumatology

Antonio Spadaro¹  Ennio Lubrano¹  Antonio Marchesoni¹  Ignazio Olivieri¹  Alessandro Mathieu¹  Carlo Salvarani¹  Raffaele Scarpa¹  Salvatore D'Angelo¹  Carlo Palazzi¹  Fabrizio Cantini¹ 

关键词: Etanercept;    spondiloarthropathies;    ankylosing spondylitis;    psoriatic arthritis;    efficacy;    Ankylosing spondylitis;    etanercept;    Psoriatic arthritis;    etanercept;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mg/twice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.

【 授权许可】

Unknown